Regulatory opportunities to encourage technology solutions to antibacterial drug resistance

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 9, 2011, Pages 1945-1947

  Finch, Roger ^a,f   Blaser, Martin ^a   Carrs, Otto ^a   Cassell, Gail ^a   Fishman, Neil ^a   Guidos, Robert ^a   Levy, Stuart ^a   Powers, John ^a   Norrby, Ragnar ^a   Tillotson, Glenn ^a   Davies, Rick ^a   Projan, Steven ^a   Dawson, Mike ^a   Monnet, Dominique ^a   Keogh Brown, Marcus ^a   Hand, Kieran ^a   Garner, Sarah ^a   Findlay, David ^a   Morel, Chantal ^a   Wise, Richard ^a   Bax, Richard ^a,b   Burke, Frances ^a,c   Chopra, Ian ^a,d   Czaplewski, Lloyd ^a,e   Livermore, David ^a,g   Piddock, Laura J V ^a,h   White, Tony ^a   more..

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b TRANSCRIP PARTNERS LLP   (United Kingdom)

^c Eli Lilly ^*  (United Kingdom)

^d UNIVERSITY OF LEEDS   (United Kingdom)

^e Biota Europe Ltd   (United Kingdom)

^f UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^g PUBLIC HEALTH ENGLAND   (United Kingdom)

^h UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Antibiotic resistance; Antibiotics; Clinical trials; Diagnostics; Drug licensing

Indexed keywords

ANTIINFECTIVE AGENT; C REACTIVE PROTEIN; ORPHAN DRUG; PLACEBO; PROCALCITONIN;

ANTIBIOTIC RESISTANCE; ARTICLE; CHRONIC BRONCHITIS; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG INDUSTRY; DRUG RESEARCH; DRUG RESPONSE; GRAM NEGATIVE BACTERIUM; HUMAN; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL (TOPIC); UPPER RESPIRATORY TRACT INFECTION; VENTILATOR ASSOCIATED PNEUMONIA;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DIFFUSION OF INNOVATION; DRUG DESIGN; DRUG RESISTANCE, BACTERIAL; HUMANS; LEGISLATION, DRUG; MICROBIOLOGY; TECHNOLOGY;

EID: 80051705390     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr259     Document Type: Article

References (11)

1. Metlay JP, Powers JH, Dudley MN et al. Antimicrobial drug resistance, regulation and research. Emerg Infect Dis 2006; 12: 183-90.
2. Williams KJ, Bax RP. Challenges in developing new antibacterial drugs. Curr Opin Invest Drugs 2009; 10: 157-63.
3. Norrby SR, Nord CE, Finch RG. Lack of development of new antimicrobial drugs: a potential serious threat to public health. Lancet 2005; 5: 115-9.
4. Boucher HW, Talbot GH, Bradley JS et al. Bad bugs, no drugs: No ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 1-12.
5. Powers JH. Risk perception and inappropriate antimicrobial use: yes, it can hurt. Clin Infect Dis 2009; 48: 1350-3.
6. Report of the British Society for Antimicrobial Chemotherapy Initiative. The Urgent Need - Regenerating Antibacterial Drug Discovery Development. http://www.bsac.org.uk/Resources/BSAC/Combined%20report%20for%20stakeholder%20day.pdf (8 April 2011, date last accessed).
7. Breimer DD. PK/PD modelling and beyond: impact on drug development. Pharm Res 2008; 25: 2720-2.
8. European Medicines Agency. Guideline on the Evaluation of Medicinal Products indicated for Treatment of Bacterial Infections. http://www.ema.europa.eu/pdfs/human/ewp/055895endraftrev2.pdf (8 April 2011, date last accessed).
9. Finch RG. Innovation - drugs and diagnostics. J Antimicrob Chemother 2007; 60 Suppl 1: 79-82.
10. Bouadma L, Luyt CE, Tubach F et al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 2010; 375: 463-74.
11. Kibe S, Adams K, Barlow G. Diagnostic and prognostic biomarkers of sepsis in critical care. J Antimicrob Chemother 2011; 66 Suppl 2: 33-40.